Dyne (DYN) news

Dyne Therapeutics, Inc.: H.C. Wainwright cuts target price to $32 from $50

H.C. Wainwright & Co. has revised its price target for Dyne Therapeutics, Inc. (NASDAQ: DYN) from $50 to $32, reflecting a 36% reduction in its projected share value [1]. The adjustment follows a reassessment of the company’s near-term clinical and commercial prospects, though the firm has not…

Dyne Therapeutics expects topline data from Achieve Rec in Q1 2027 with primary endpoint vhot at 6 months

Dyne Therapeutics, Inc. (Nasdaq: DYN) has announced that topline data from the registrational expansion cohort (REC) of its Phase 1/2 ACHIEVE trial of zeleciment basivarsen (z-basivarsen, DYNE-101) in myotonic dystrophy type 1 (DM1) is expected in the first quarter of 2027. The primary endpoint for…

Dyne Therapeutics, - Reports improvement at 6 months in vhot with Z-basivarsen in DM1

Dyne Therapeutics is conducting a Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy type 1 (DM1) under the trial identifier NCT07486934. The trial, which began on May 14, 2026, is expected to…

Dyne Therapeutics announces additional one-year clinical data from phase 1/2 achieve trial of Z-basivarsen (Dyne-101) for myotonic dystrophy type 1 (DM1)

Sarepta Therapeutics down 11.4%, Dyne Therapeutics down 22%

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and Dyne Therapeutics, Inc. (NASDAQ: DYN) both experienced significant declines in after-hours trading on September 8, 2026, with Sarepta down 11.4% and Dyne down 22%. The drop in Dyne shares followed the company’s announcement of a completed upsized public…